Analysts on Wall Street project that BioMarin Pharmaceutical (BMRN) will announce quarterly earnings of $0.57 per share in its forthcoming report, representing an increase of 5.6% year over year. Revenues are projected to reach $660.51 million, increasing 11% from the same quarter last year.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections ov ...